Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John P Fischer

Showing results (261-270 of 267) with videos related to

Pageof 27
Sort By:
You have reached the last page of results.This site can display upto 267 results.
The British Journal of Surgery|August 26, 2022
Updated guideline for closure of abdominal wall incisions from the European and American Hernia SocietiesEva B Deerenberg, Nadia A Henriksen, George A Antoniou, et al.
Surgery|April 30, 2018
Contemporary concepts in hernia prevention: Selected proceedings from the 2017 International Symposium on Prevention of Incisional HerniasHobart W Harris, William H Hope, Gina Adrales, et al.
Journal of Medicinal Chemistry|December 10, 2021
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS<sup>G12D</sup> InhibitorXiaolun Wang, Shelley Allen, James F Blake, et al.
ACS Medicinal Chemistry Letters|January 8, 2019
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo ActivityJay B Fell, John P Fischer, Brian R Baer, et al.
Cancer Discovery|October 30, 2019
The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and PatientsJill Hallin, Lars D Engstrom, Lauren Hargis, et al.
Journal of Medicinal Chemistry|April 7, 2020
Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS<sup>G12C</sup> Inhibitor for the Treatment of CancerJay B Fell, John P Fischer, Brian R Baer, et al.
ACS Medicinal Chemistry Letters|February 19, 2025
Design of Potent Menin-KMT2A Interaction Inhibitors with Improved <i>In Vitro</i> ADME Properties and Reduced hERG AffinityBruno D Chapsal, Jennifer R Kimbrough, Stephanie M Bester, et al.
Pageof 27

Showing results (261-270 of 267) with videos related to

Sort By:
Pageof 27
You have reached the last page of results.This site can display upto 267 results.
The British Journal of Surgery|August 26, 2022
Updated guideline for closure of abdominal wall incisions from the European and American Hernia SocietiesEva B Deerenberg, Nadia A Henriksen, George A Antoniou, et al.
Surgery|April 30, 2018
Contemporary concepts in hernia prevention: Selected proceedings from the 2017 International Symposium on Prevention of Incisional HerniasHobart W Harris, William H Hope, Gina Adrales, et al.
Journal of Medicinal Chemistry|December 10, 2021
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS<sup>G12D</sup> InhibitorXiaolun Wang, Shelley Allen, James F Blake, et al.
ACS Medicinal Chemistry Letters|January 8, 2019
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo ActivityJay B Fell, John P Fischer, Brian R Baer, et al.
Cancer Discovery|October 30, 2019
The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and PatientsJill Hallin, Lars D Engstrom, Lauren Hargis, et al.
Journal of Medicinal Chemistry|April 7, 2020
Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS<sup>G12C</sup> Inhibitor for the Treatment of CancerJay B Fell, John P Fischer, Brian R Baer, et al.
ACS Medicinal Chemistry Letters|February 19, 2025
Design of Potent Menin-KMT2A Interaction Inhibitors with Improved <i>In Vitro</i> ADME Properties and Reduced hERG AffinityBruno D Chapsal, Jennifer R Kimbrough, Stephanie M Bester, et al.
Pageof 27